PET/CT imaging of esophageal cancer targeting tumor cell specific αvβ6-integrin expression
European Journal of Nuclear Medicine and Molecular Imaging · 2025-12 · 53 (1) · 607-618
DOI: 10.1007/s00259-025-07408-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 20.06.2025. Verfasst von Kateřina Dvořáková Bendová und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Positron Emission Tomography Computed Tomography, Integrins, Antigens, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technische Universität München.
Abstract (Originalsprache)
Purpose
To assess the potential of αvβ6-integrin as a theranostic target in esophageal cancer.
Methods
Membranous β6-integrin (ITGB6) expression was analyzed in 306 specimens of human esophageal squamous cell carcinoma (ESCC) obtained by immunohistochemistry (IHC) from 100 patient cases (1, 37, 58, and 4 of grade G1, G2, G3, and G4, respectively). Ga-68 labeling of D0103 was done manually for preclinical experiments and fully automated for clinical application. Preclinical characterization of Ga-68-D0103 was performed in SCID mice bearing subcutaneous xenografts of H2009 (αvβ6-positive) or MDA-MB-231 (αvβ6-negative) carcinoma cell lines, by ex vivo biodistribution (10, 30, 90, and 180 min p.i) and PET imaging (30, 90, and 180 min p.i.)., without and with co-injection of gelofusine (4% succinylated gelatin). A patient with type-II diabetes (f, 68y, 115 kg) with proximal G2 ESCC was investigated by Ga-68-D0103 PET/CT (193 MBq) at 15, 45, 90, and 104 min p.i..
Results
99% of ESCC cases were found β6-integrin positive by IHC, of which 48%, 31%, and 20% showed strong, moderate, and low ITGB6 expression, respectively, with no correlation to tumor grade. Ex vivo biodistribution of Ga-68-D0103 in H2009 xenografted mice after 30, 90, and 180 min showed tumor-to-blood ratios of 6.8, 37, and 124, respectively; tumor-to-muscle ratios of 12, 14, and 36, respectively; tumor-to-liver ratios of 10, 17, and 14, respectively; and tumor-to-pancreas ratios of 20, 47, and 56, respectively. Co-administration of gelofusine did not change the tumor uptake but reduced the kidney uptake by 89% (from 178%iA/g to 19.1%iA/g, 90 min p.i.), resulting in an 8.7-fold higher tumor/kidney ratio. µPET imaging in H2009 xenografted mice confirmed a high tumor uptake and low background already 30 min p.i.. Blockade biodistribution and µPET in αvβ6-(–) MDA-MB-231 mice demonstrated target specificity. Clinical PET/CT of a patient with ESCC showed increasing tracer uptake over time in the primary tumor (SUVmax 9.0 and 11.3 at 15 and 104 min p.i., respectively) and in a lymph node metastasis (SUVmax 19.5 and 28.3, respectively), and a decreasing blood pool activity (SUVmean 2.75 and 0.98, respectively).
Conclusions
High (99%) membranous expression frequency and density on tumor cells underscores the potential of αvβ6-integrin as a theranostic target in ESCC, suggesting that αvβ6-integrin PET/CT imaging may adopt a role in re-staging and therapy guidance in this cancer type. The prolonged tumor retention furthermore indicates a therapeutic potential of αvβ6-integrin targeted radiopharmaceuticals when labeled with radionuclides such as lutetium-177, terbium-161, or actinium-225.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
- Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany.
- Czech Advanced Technology and Research Institute, Palacký University Olomouc, Olomouc, Czech Republic.
- TRIMT GmbH, Carl-Eschebach-Str. 7, 01454, Radeberg, Germany.
- Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
- Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, University Hospital Olomouc, Olomouc, Czech Republic.
ORCID-Profile: Johannes Notni
Förderung
- Technische Universität München
Zitieren
APA
Bendová, K. D., Groll, T., Neužilová, B., Krasulová, K., Nový, Z., Reissig, F., Steiger, K., Boxberg, M., Eppard, E., Wuestemann, J., Hajdúch, M., Jesinghaus, M., Šimeček, J., Kreissl, M. C., Petřík, M., & Notni, J. (2025). PET/CT imaging of esophageal cancer targeting tumor cell specific αvβ6-integrin expression. European Journal of Nuclear Medicine and Molecular Imaging, 53(1), 607-618. https://doi.org/10.1007/s00259-025-07408-7
Vancouver
Bendová KD, Groll T, Neužilová B, Krasulová K, Nový Z, Reissig F, et al. PET/CT imaging of esophageal cancer targeting tumor cell specific αvβ6-integrin expression. European Journal of Nuclear Medicine and Molecular Imaging. 2025;53(1):607-618. doi:10.1007/s00259-025-07408-7
BibTeX
@article{Bendov2025,
author = {Bendová, Kateřina Dvořáková and Groll, Tanja and Neužilová, Barbora and Krasulová, Kristýna and Nový, Zbyněk and Reissig, Falco and Steiger, Katja and Boxberg, Melanie and Eppard, Elisabeth and Wuestemann, Jan and Hajdúch, Marián and Jesinghaus, Moritz and Šimeček, Jakub and Kreissl, Michael C and Petřík, Miloš and Notni, Johannes},
title = {PET/CT imaging of esophageal cancer targeting tumor cell specific αvβ6-integrin expression},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {53},
number = {1},
pages = {607--618},
doi = {10.1007/s00259-025-07408-7}
}
EUVIMED